Jefferies assumed coverage of MBX Biosciences (MBX) with a Buy rating and $36 price target The firm believes that if canvuparatide can show a 50%-60% response and favorable safety in the upcoming Phase 2 readout, the stock could see 50%-100% upside potential. In this case MBX could move into Phase 3 with a competitive profile and capture “decent” future hypoparathyroidism market share, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX: